Relmada Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is focused on developing treatments for central nervous system (CNS) disorders. Its product candidate includes dextromethadone (d-methadone), REL-1017, REL-1015 (LevoCap ER), REL-1028 (BuTab) and REL-1021 (MepiGel). d-methadone (dextromethadone, REL-1017) is an N-methyl-D-aspartate (NMDA) receptor antagonist. d-methadone is a new chemical entity (NCE) that is being developed for the treatment of central nervous system (CNS) diseases and other disorders. It is also being developed for the treatment of depression, ophthalmological disorders and/or other potential indications. REL-1015 (LevoCap ER) product candidate is an extended release, abuse deterrent, proprietary formulation of the opioid analgesic levorphanol. REL-1028 is a novel oral formulations of modified release buprenorphine. MepiGel is a topical dosage form of the local anesthetic mepivacaine.